Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Accounts Payables (2016 - 2025)

Haemonetics has reported Accounts Payables over the past 16 years, most recently at $48.7 million for Q4 2025.

  • Quarterly results put Accounts Payables at $48.7 million for Q4 2025, down 22.7% from a year ago — trailing twelve months through Dec 2025 was $48.7 million (down 22.7% YoY), and the annual figure for FY2025 was $67.0 million, down 8.67%.
  • Accounts Payables for Q4 2025 was $48.7 million at Haemonetics, down from $61.7 million in the prior quarter.
  • Over the last five years, Accounts Payables for HAE hit a ceiling of $80.2 million in Q3 2023 and a floor of $45.0 million in Q4 2021.
  • Median Accounts Payables over the past 5 years was $61.6 million (2022), compared with a mean of $61.1 million.
  • Biggest five-year swings in Accounts Payables: surged 36.73% in 2022 and later plummeted 40.19% in 2025.
  • Haemonetics' Accounts Payables stood at $45.0 million in 2021, then soared by 41.81% to $63.8 million in 2022, then dropped by 10.86% to $56.8 million in 2023, then rose by 10.81% to $63.0 million in 2024, then dropped by 22.7% to $48.7 million in 2025.
  • The last three reported values for Accounts Payables were $48.7 million (Q4 2025), $61.7 million (Q3 2025), and $46.0 million (Q2 2025) per Business Quant data.